Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Norway Savings Bank

Norway Savings Bank lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.4% in the fourth quarter, HoldingsChannel reports. The firm owned 8,571 shares of the medical equipment provider’s stock after selling 486 shares during the quarter. Norway Savings Bank’s holdings in Zimmer Biomet were worth $905,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC lifted its stake in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the 3rd quarter valued at about $31,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the 3rd quarter worth about $35,000. Finally, Quarry LP acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $53,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 0.4 %

ZBH stock traded down $0.38 during mid-day trading on Tuesday, reaching $103.18. 836,731 shares of the stock traded hands, compared to its average volume of 1,165,927. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The stock’s fifty day moving average is $108.38 and its 200-day moving average is $108.18. The company has a market cap of $20.54 billion, a P/E ratio of 19.62, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the business posted $1.65 EPS. The company’s revenue was up 4.1% on a year-over-year basis. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Raymond James decreased their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Evercore ISI lowered their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Truist Financial boosted their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.